What question did this study set out to answer?

The aim is to characterize the clinical features and treatment outcomes of adolescents and young adults with myeloproliferative neoplasms (MPNs).

Clinical features, management, and outcomes of adolescents and young adults with myeloproliferative neoplasms.

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study examines outcomes in adolescents with myeloproliferative neoplasms, suggesting need for tailored treatment guidelines.

The aim is to characterize the clinical features and treatment outcomes of adolescents and young adults with myeloproliferative neoplasms (MPNs).
Conducted a retrospective study of 90 adolescents and young adults with MPN treated at Mass General Brigham from 2007 to 2025.
Inclusion based on age (13-39) and meeting WHO criteria for MPN.
Collected data on demographics, cardiovascular risk factors, thrombotic and bleeding events, and management approaches.
65.6% had essential thrombocythemia, 22.2% had polycythemia vera, and 6.7% had myelofibrosis.
58.9% presented with at least one cardiovascular risk factor; median follow-up was 3.6 years with 4.4% progressing to myelofibrosis.
47.9% of low-risk patients received cytoreduction, highlighting limitations in current risk stratification.

Pino-Ascencio et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective study examines outcomes in adolescents with myeloproliferative neoplasms, suggesting need for tailored treatment guidelines.